At the Breakthroughs in Muscular Dystrophy special meeting held in Chicago Nov. 19-20, 2024, and organized by the American Society of Gene & Cell Therapy (ASGCT), multiple interventions at the RNA level were among the approaches that were presented to fight muscular dystrophies. Read More
Anocca AB has submitted its first clinical trial application (CTA) to the EMA for a phase I/II multi-asset umbrella trial, VIDAR-1. The application covers ANOC-001 as the initial product in the VIDAR-1 program targeting mutated KRAS in advanced pancreatic cancer.
Longbio Pharma (Suzhou) Co. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for LP-003, the company’s next-generation anti-IgE antibody, to enter a clinical trial for the treatment of food allergy. Read More
Researchers from Pyxis Oncology Inc. presented preclinical data for PYX-201, an antibody drug conjugate (ADC) that targets extra domain B of fibronectin (EDB+FN). Read More
Scenic Immunology BV has disclosed glutaminyl-peptide cyclotransferase (QPCT; QC) and/or glutaminyl-peptide cyclotransferase-like protein (QPCTL; isoQC) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Astrazeneca plc presented the discovery and preclinical characterization of AZD-9793, a novel CD8-guided T-cell engager (TCE) being developed for the treatment of hepatocellular carcinoma (HCC). Read More
Secretome Therapeutics Inc. has closed a $20.4 million round of financing to support its development of therapies derived from neonatal cardiac progenitor cells. Read More
Enanta Pharmaceuticals Inc. has announced the expansion of its immunology portfolio with the nomination of a new development candidate and the introduction of a new discovery program. Read More
Scientists at Institució Catalana de Recerca i Estudis Avançats and Universitat de Barcelona have identified three-prime repair exonuclease 2 (TREX2) inhibitors reported to be useful for the treatment of psoriasis, atopic dermatitis and ichthyosis. Read More
Empyrean Therapeutics Inc. has acquired a first-in-class TLR2 antagonist molecule from Eos Therapies Inc. with the aim of treating brain, pancreatic, breast and other hard-to-treat cancers. Read More
Septerna Inc. has divulged compounds acting as mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of asthma, cancer, multiple sclerosis, obesity, osteoarthritis, psoriasis, rheumatoid arthritis and ulcerative colitis, among others. Read More
Shandong Luye Pharmaceutical Co. Ltd. has described gonadotropin-releasing hormone receptor (GNRHR) antagonists reported to be useful for the treatment of acne, cancer, dysmenorrhea, endometriosis, uterine fibroids (myoma), infertility, precocious puberty and premenstrual syndrome, among others. Read More
WD repeat domain 83 opposite strand (WDR83OS) encodes the 106-aa (amino acid) protein Asterix, which is a binding partner for CCDC47. More specifically, Asterix heterodimerizes with CCDC47 to form the protein associated with ER translocon (PAT) complex that specifically chaperones large proteins containing transmembrane domains. Read More
